Cargando…

Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study

PURPOSE: Pasireotide is an effective treatment for acromegaly and Cushing’s disease, although treatment-emergent hyperglycemia can occur. The objective of this study was to assess incretin-based therapy versus insulin for managing pasireotide-associated hyperglycemia uncontrolled by metformin/other...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samson, Susan L., Gu, Feng, Feldt-Rasmussen, Ulla, Zhang, Shaoling, Yu, Yerong, Witek, Przemysław, Kalra, Pramila, Pedroncelli, Alberto M., Pultar, Philippe, Jabbour, Nadine, Paul, Michaela, Bolanowski, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550309/ https://www.ncbi.nlm.nih.gov/pubmed/34275099 http://dx.doi.org/10.1007/s11102-021-01161-4

Ejemplares similares

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide
por: Samson, Susan Leanne, et al.
Publicado: (2023)

Pasireotide—a novel somatostatin receptor ligand after 20 years of use
por: Bolanowski, Marek, et al.
Publicado: (2022)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
por: Witek, Przemysław, et al.
Publicado: (2021)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia
por: Gordon, Murray B, et al.
Publicado: (2017)

THU066 An 8-year Interim Report Of The B2412 Study, An Open-label, Multicenter Pasireotide Rollover Study For Patients Who Continued To Receive Benefit From Pasireotide At Completion Of An Earlier Trial
por: Gadelha, Mônica, et al.
Publicado: (2023)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
por: Lacroix, André, et al.
Publicado: (2019)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Medical treatment of Cushing’s disease with concurrent diabetes mellitus
por: Mehlich, Anna, et al.
Publicado: (2023)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Radioiodine treatment for non-toxic goitre
por: Feldt-Rasmussen, Ulla
Publicado: (2009)

Pasireotide and octreotide in the treatment of severe late dumping syndrome
por: Mohammadi, Alireza, et al.
Publicado: (2017)

A prospective longitudinal study of Pasireotide in Nelson’s syndrome
por: Daniel, Eleni, et al.
Publicado: (2018)

PMON162 Osilodrostat Provides Sustained Clinical Benefits and Improves Health-Related Quality of Life in Patients with Cushing's Disease: Results from the Phase III LINC 4 Study
por: Feelders, Richard, et al.
Publicado: (2022)

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
por: Shikata, Masato, et al.
Publicado: (2020)

Efficacy of pasireotide in controlling severe hypercortisolism until cardiac transplantation
por: Attanasio, Roberto, et al.
Publicado: (2017)

Rapid response of Nelson’s syndrome to pasireotide in radiotherapy-naive patient
por: He, Xin, et al.
Publicado: (2020)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Impact of pasireotide on postoperative pancreatic fistulas following distal resections
por: Vuorela, Tiina, et al.
Publicado: (2021)

Introduction to European comments on “Medullary Thyroid Cancer: management guidelines of the American Thyroid Association”
por: Jarzab, Barbara, et al.
Publicado: (2013)

Results and summary of voting among the audience during presentation and discussion of Medullary Thyroid Carcinoma clinical guidelines prepared by American Thyroid Association
por: Feldt-Rasmussen, Ulla, et al.
Publicado: (2013)

Hypopituitarism in Traumatic Brain Injury—A Critical Note
por: Klose, Marianne, et al.
Publicado: (2015)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma
por: Rajendran, Rajesh, et al.
Publicado: (2013)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism
por: Gostelow, R., et al.
Publicado: (2017)

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature
por: Oziel-Taieb, Sandrine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nh7sfmvjq4s3ag0ek53kssa6t8